China’s Akeso has made a name for itself on the world stage by cutting a potential $5bn licensing deal with US biotech Summit in December 2022. Michelle Xia, founder, chairwoman and CEO of the biopharma, is beginning to look beyond the deal, describing it one of the first steps for Akeso to develop and commercialize innovative drugs globally on its own.

Time marks:

Introduction

Licensing deal with Summit Therapeutics (00:20)

Latest progress of the partnership (01:33)

Ivonescimab’s potential breakthrough (03:21)

Akeso’s journey (04:51)

Platform buildup and choice of targets (07:22)

Cadonilimab versus PD-1 (11:32)

Licensing prospects of cadonilimab (14:43)

Bispecific antibody versus ADC (17:10)

Rationale behind deal-making (19:50)

Go global on its own (22:20)

Closing

Akeso's Xia Looks Beyond Summit Deal To Independent Global Development, Sales:

https://scrip.pharmaintelligence.informa.com/SC147939/Akesos-Xia-Looks-Beyond-Summit-Deal-To-Independent-Global-Development-Sales